BR112018006880A2 - terapia de combinação - Google Patents

terapia de combinação

Info

Publication number
BR112018006880A2
BR112018006880A2 BR112018006880-2A BR112018006880A BR112018006880A2 BR 112018006880 A2 BR112018006880 A2 BR 112018006880A2 BR 112018006880 A BR112018006880 A BR 112018006880A BR 112018006880 A2 BR112018006880 A2 BR 112018006880A2
Authority
BR
Brazil
Prior art keywords
alaninyl
phosphate
combination therapy
combination
phenylbenzoxy
Prior art date
Application number
BR112018006880-2A
Other languages
English (en)
Other versions
BR112018006880B1 (pt
Inventor
Griffith Hugh
Original Assignee
NuCana plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NuCana plc filed Critical NuCana plc
Publication of BR112018006880A2 publication Critical patent/BR112018006880A2/pt
Publication of BR112018006880B1 publication Critical patent/BR112018006880B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

a presente invenção se refere a uma combinação de gencitabina-[fenil-benzóxi-l-alaninil)]-fosfato (nome químico: 2'-desoxi-2',2'-difluoro-d-citidina-5'-o-[fenil (benzóxi-l-alaninil)]fosfato) (nuc-1031) e um agente anticâncer com base em platina selecionado a partir de carboplatina, dicicloplatina, oxaliplatina, satraplatina e nedaplatina. as combinações são úteis no tratamento de câncer e, particularmente, câncer ovariano.
BR112018006880-2A 2015-10-05 Uso de gencitabina-[fenil-benzóxi-l-alaninil)]-fosfato ou um sal farmaceuticamente aceitável ou solvato da mesma e carboplatina no tratamento de câncer BR112018006880B1 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2015/052902 WO2017060661A1 (en) 2015-10-05 2015-10-05 Combination therapy

Publications (2)

Publication Number Publication Date
BR112018006880A2 true BR112018006880A2 (pt) 2018-10-16
BR112018006880B1 BR112018006880B1 (pt) 2023-07-11

Family

ID=

Also Published As

Publication number Publication date
EP3359163A1 (en) 2018-08-15
CN108135920A (zh) 2018-06-08
KR20180063075A (ko) 2018-06-11
CA2994502C (en) 2023-08-01
AU2015411525B2 (en) 2021-08-12
CA2994502A1 (en) 2017-04-13
MX2018004137A (es) 2018-06-13
US20180271889A1 (en) 2018-09-27
WO2017060661A1 (en) 2017-04-13
US20200268783A1 (en) 2020-08-27
IL257976A (en) 2018-05-31
EP3359163B1 (en) 2023-12-20
AU2015411525A1 (en) 2018-03-15
JP7038653B2 (ja) 2022-03-18
JP2018529740A (ja) 2018-10-11
JP2022001599A (ja) 2022-01-06
PH12018500691A1 (en) 2018-10-15
EA037248B1 (ru) 2021-02-26
US20220323475A1 (en) 2022-10-13
EA201890894A1 (ru) 2018-09-28
US10660912B2 (en) 2020-05-26

Similar Documents

Publication Publication Date Title
PH12018500691A1 (en) Combination therapy
MX2015011752A (es) Metodos para tratar cancer de pulmon.
CY1118216T1 (el) Μεθοδοι αγωγης καρκινου
PH12018501339A1 (en) Combination therapy
BR112018013808A2 (pt) dinucleotídeos cíclicos para o tratamento de condições associadas à atividade de sting, tal como câncer
PH12018502535A1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
BR112018067368A2 (pt) terapia de combinação com anticorpos anti-cd73
MY197198A (en) Pharmaceutical composition for preventing or treating breast cancer including crystalline polymorph of tetraarsenic hexoxide, and method for producing same
MX2020009223A (es) Anticuerpos anti-fgfr2iiib afucosilados.
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
BR112017018318A2 (pt) composição farmacêutica para tratar câncer compreendendo microrna como ingrediente ativo
MY198613A (en) Nitrobenzyl derivatives of anti-cancer agents
BR112018007395A2 (pt) 2,4-di-hidróxi-nicotinamidas como agonistas de apj
BR112019022280A2 (pt) tratamento de cânceres de her2 positivo
EA201791182A1 (ru) Новые производные 2'- и/или 5'-аминокислотных эфиров фосфороамидатов 3'-дезоксиаденозина в качестве противораковых соединений
TR201901077T4 (tr) Kanser Veya Enfeksiyon Tedavisine Yönelik Birleşik Preparasyonlar
MX2018006953A (es) Compuestos de platino funcionalizados con monomaleimida para la terapia del cancer.
WO2016160621A3 (en) Nk-92 cells in combination therapy with cancer drugs
CY1122968T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει μια ενωση διαμινο-ετεροκυκλικου καρβοξαμιδιου ως δραστικο συστατικο
NZ631082A (en) Methods for treating cancer using tor kinase inhibitor combination therapy
MX2019005349A (es) Uso de analogos de sangliferina macrociclicos como compuestos anticancerigenos.
BR112019004906A2 (pt) combinação incluindo abx196 para o tratamento de câncer
BR112019005825A2 (pt) vírus envelopado modificado, composição farmacêutica, e, método para tratar um câncer
BR112019025164A2 (pt) Esquema de dosagem para tesetaxel e capecitabina
WO2020067910A3 (en) Pharmaceutical formulation containing a selenitetriglyceride and a cytostatic for use in treatment of tumour

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/10/2015, OBSERVADAS AS CONDICOES LEGAIS